Anti-Microbialvior BioteQ Co (ROCO:6864) Cash-to-Debt : 56.71 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Anti-Microbialvior BioteQ Co Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Anti-Microbialvior BioteQ Co's cash to debt ratio for the quarter that ended in Dec. 2023 was 56.71.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Anti-Microbialvior BioteQ Co could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Anti-Microbialvior BioteQ Co's Cash-to-Debt or its related term are showing as below:

ROCO:6864' s Cash-to-Debt Range Over the Past 10 Years
Min: 5.88 Med: 27.79 Max: No Debt
Current: 56.71

During the past 6 years, Anti-Microbialvior BioteQ Co's highest Cash to Debt Ratio was No Debt. The lowest was 5.88. And the median was 27.79.

ROCO:6864's Cash-to-Debt is ranked better than
73.61% of 1527 companies
in the Biotechnology industry
Industry Median: 6.24 vs ROCO:6864: 56.71

Anti-Microbialvior BioteQ Co Cash-to-Debt Historical Data

The historical data trend for Anti-Microbialvior BioteQ Co's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Anti-Microbialvior BioteQ Co Cash-to-Debt Chart

Anti-Microbialvior BioteQ Co Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

5.88

22.69

11.78

32.89

56.71

Anti-Microbialvior BioteQ Co Semi-Annual Data
	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial				11.78	10.66	32.89	38.84	56.71

Competitive Comparison of Anti-Microbialvior BioteQ Co's Cash-to-Debt

For the Biotechnology subindustry, Anti-Microbialvior BioteQ Co's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Anti-Microbialvior BioteQ Co's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Anti-Microbialvior BioteQ Co's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Anti-Microbialvior BioteQ Co's Cash-to-Debt falls into.

Anti-Microbialvior BioteQ Co Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Anti-Microbialvior BioteQ Co's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	78.427	/	(1.383	+	0)
	=	56.71

Anti-Microbialvior BioteQ Co's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	78.427	/	(1.383	+	0)
	=	56.71

Anti-Microbialvior BioteQ Co (ROCO:6864) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Anti-Microbialvior BioteQ Co Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Anti-Microbialvior BioteQ Co's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Anti-Microbialvior BioteQ Co (ROCO:6864) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Anti-Microbial Savior BioteQ Co Ltd (ROCO:6864) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

Sec.1, Huandong Road, 1 Floor, No. 2, Ln. 31, Xinshi District, Tainan, TWN, 741

Website

https://www.ams-bioteq.com

Anti-Microbial Savior BioteQ Co Ltd is engaged in drug research and development as well as development and technology patenting of medical fungi.

Anti-Microbialvior BioteQ Co (ROCO:6864) Headlines

No Headlines